Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Janine Mans"'
Publikováno v:
Volume: 4, Issue: 3 233-246
International Journal of Health Services Research and Policy
Vincent Okungu
International Journal of Health Services Research and Policy, Vol 4, Iss 3, Pp 233-246 (2019)
International Journal of Health Services Research and Policy
Vincent Okungu
International Journal of Health Services Research and Policy, Vol 4, Iss 3, Pp 233-246 (2019)
The aim of this assessment was to understand whether financing for maternal, child health and immunization services are sustainable, efficient, effective and equitable. Data sources included various national and international reports related to finan
Autor:
Janine Mans, Vincent Okungu
Publikováno v:
Volume: 4, Issue: 2 131-144
International Journal of Health Services Research and Policy
International Journal of Health Services Research and Policy, Vol 4, Iss 2, Pp 131-144 (2019)
International Journal of Health Services Research and Policy
International Journal of Health Services Research and Policy, Vol 4, Iss 2, Pp 131-144 (2019)
Decreasing external funding for malaria requires high burden countries such as Uganda to increase domestic public financing to control and eliminate malaria. The aim of this study was to examine how the Government of Uganda, in collaboration with dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d966f5aa04971092aeeab05972f54e7
https://dergipark.org.tr/tr/pub/ijhsrp/issue/48345/575194
https://dergipark.org.tr/tr/pub/ijhsrp/issue/48345/575194
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Autor:
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Alicia Bravo, Emily Foulstone, Saiqa Spensley, Rebecca Bowen, Janine Mansi, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Jeremy Braybrooke, Charles Comins, Vivek Mohan, Abigail Gee, Hannah Kirk, Alison Markham, Heidi Evans, Eve Watson, Mark Callaway, Sylvia Pearson, Allan Hackshaw, Mark Churn
Publikováno v:
Breast, Vol 66, Iss , Pp 69-76 (2022)
Background: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5–53.7% and significant risk of peripheral neuropathy, there is need for better chemoth
Externí odkaz:
https://doaj.org/article/82333b9202654f2ab93e6857aabae51e
Publikováno v:
Transportation Research Record: Journal of the Transportation Research Board. 2323:90-98
Transportation behavior appears to have shifted in recent years. Between the 2001 and 2009 National Household Travel Surveys, the average annual vehicle miles traveled for all age brackets fell. This reduction in driving is likely to be related to a
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/4ff05e79a58f49b980db63215fe0a4b3
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77